Efficacy of combination therapy of pimecrolimus 1% cream and mometasone cream with either agent alone in the treatment of childhood vitiligo

Saeedeh Farajzadeh, Iraj Esfandiarpour, Elham Poor Khandani, Ali Ekhlasi, Soheyla Safari, Sadegh Hasheminasab Gorji, Mahin Aflatoonian, Saman Mohammadi, Maryam Khalili, Behrooz Vares

Abstract


Objective To evaluate the efficacy of the combination therapy of mometasone and pimecrolimus in the treatment of vitiligo in children.

 

Methods In this double-blind randomized controlled trial, 50 patients were enrolled. Based on the planned treatment protocol, three lesions with approximately identical size at similar anatomic sites were selected in each patient. Lesions were divided to three groups: pimecrolimus cream 1 % (twice a day), mometasone furoate ointment 0.1 % (every night), and combined therapy group (pimecrolimus twice a day on weekdays and mometasone every night on weekends), all being applied for three months. They were followed up for three months.

 

Results Forty patients (with 46% of cases being male) with a mean age of 10.6 years completed the study. There was no significant difference in response rate between three groups at the end of the treatment.

 

Conclusion Our study results did not demonstrate significant difference in the response rate and adverse effects between combined treatment group and either alone.

 


Keywords


Pimecrolimus, Mometasone; Vitiligo; Children

Full Text:

PDF

References


Farajzadeh S, Aflatoonian M, Mohammadi S, Vares B, Amiri R. Epidemiological aspects and disease association of childhood vitiligo. J Pak Assoc Dermatol. 2015;15:105-10.

Boissy RE, Nordlund JJ. Vitiligo: current medical and scientific understanding. J Ital Dermatol Venereol. 2011;146:69-75.

Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a review of the published work. J Dermatol. 2011;38:419-31.

Sandoval-Cruz M, García-Carrasco M, Sánchez-Porras R, Mendoza-Pinto C, Jiménez-Hernández M, Munguía-Realpozo P et al. Immunopathogenesis of vitiligo. Autoimmun Rev. 2011;10:762-5.

Kwinter J, Pelletier J, Khambalia A, Pope E. High-potency steroid use in children with vitiligo: A retrospective study. J Am Acad Dermatol. 2007;56:236-41.

Ho N, Pope E, Weinstein M, Greenberg S, Webster C, Krafchik BR. A double-blind, randomized, placebo-controlled trial of topical tacrolimus 0•1% vs. clobetasol propionate 0•05% in childhood vitiligo. Br J Dermatol. 2011; 165:626-32.

Brazzelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A, Borroni G. Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60cases treated with ultraviolet B narrow-band phototherapy. J Eur Acad Dermatol Venereol. 2007;21:1369-74.

Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A Double-blind Randomized Trial of 0.1% Tacrolimus vs 0.05% Clobetasol for the treatment of Childhood Vitiligo. Arch Dermatol. 2003;139:581-5.

Köse O, Arca E, Kurumlu Z. Mometasone cream versus pimecrolimus cream for the treatment of childhood localized vitiligo. J Dermatology Treat. 2010;21(3):133-9.

Nordal E, Guleng G, Rönnevig J. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) Vs. placebo ointment, a randomized right/left double-blind comparative study. J Eur Acad Dermatol Venereol. 2011;25:1440-3.

Luger Th, Paul C. Potential New Indications of Topical Calcineurin Inhibitors. Dermatology. 2007;215:45-54.

Farajzadeh S, Daraei Z, Esfandiarpour I, Hosseini H. The Efficacy of Pimecrolimus1% Cream Combined with Microdermabrasion in the Treatment of Nonsegmental Childhood Vitiligo: A Randomized Placebo–Controlled Study. Pediatr Dermatol. 2009;26:286-91.

Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol. 2002;147:316-23.

Coskun B, Saral Y, Turgut D. Topical 0.05% Clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur J Dermatol. 2005;15:88-91.

Silverberg NB, Lin P, Travis L, Farley-Li J, Mancini AJ, Wagner AM et al. Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. J Am Acad Dermatol. 2004;51:760-6.

Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy pimecrolimus 1% cream plus narrow band ultraviolet B in the treatment of vitiligo: A double blind, placebo-controlled trial. J Dermatolog Treat. 2008;16:1-5.

Kostovic K, PasicA. New Treatment Modalities for Vitiligo: Focus on Topical Immunomodulators. Drug. 2005;65:447-59.

Barikbin B, Kardan G, Yousefi M. Does Pimecrolimus Cream Enhance the Effect of Excimer Laser on Eyelid Vitiligo? J Lasers Med Sci. 2011;2:26-9.

Wong R, Lin AN. Efficacy of topical calcineurin inhibitors in vitiligo. Int J Dermatol. 2013;52:491-6.


Refbacks

  • There are currently no refbacks.


ISSN: 1560-9014